Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN7041
- Development stage
- Discontinued
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN7041 is an experimental monoclonal antibody developed by Regeneron Pharmaceuticals that targets the CD3 receptor complex on T-cells. By binding to CD3, REGN7041 is designed to modulate T-cell-mediated immune responses and suppress the inflammatory pathways that drive autoimmune and inflammatory conditions. The drug is currently being investigated as a systemic treatment for active noninfectious uveitis affecting the posterior segment of the eye, where it aims to reduce intraocular inflammation and prevent tissue damage. As a first-in-human therapy in this indication, it is undergoing evaluation for safety, tolerability, and pharmacokinetics in both the blood and ocular fluid.
02
Targets
CD3E (T-cell surface glycoprotein CD3 epsilon chain)
Beyond the preview
Go deeper on REGN7041.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN7041.